You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 4, 2024

CLINICAL TRIALS PROFILE FOR TRILACICLIB DIHYDROCHLORIDE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for TRILACICLIB DIHYDROCHLORIDE

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02499770 ↗ Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC) Completed G1 Therapeutics, Inc. Phase 1/Phase 2 2015-06-26 This is a study to investigate the potential clinical benefit of trilaciclib (G1T28) in preserving the bone marrow and the immune system, and enhancing chemotherapy antitumor efficacy when administered prior to carboplatin and etoposide in first line treatment for patients with newly diagnosed extensive-stage SCLC. The study consists of 2 parts: a limited open-label, dose-finding portion (Part 1), and a randomized double-blind portion (Part 2). Both parts include 3 study phases: Screening Phase, Treatment Phase, and Survival Follow-up Phase. The Treatment Phase begins on the day of first dose with study treatment and completes at the Post-Treatment Visit. Approximately, 90 patients will be enrolled in the study; 20 patients in the Part 1 and 70 patients in the Part 2 portion.
NCT02514447 ↗ Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy Active, not recruiting G1 Therapeutics, Inc. Phase 1/Phase 2 2015-10-05 This is a study to investigate the potential clinical benefit of trilaciclib (G1T28) in preserving the bone marrow and the immune system, and enhancing chemotherapy antitumor efficacy when administered prior to topotecan in patients previously treated for extensive-stage SCLC. The study consists of 2 parts: a limited open-label, dose-finding portion (Part 1), and a randomized double-blind portion (Part 2). Both parts include 3 study phases: Screening Phase, Treatment Phase, and Survival Follow-up Phase. The Treatment Phase begins on the day of first dose with study treatment and completes at the Post-Treatment Visit. The open-label portion enrolled 32 patients and the randomized portion will enroll approximately 90 patients.
NCT02978716 ↗ Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC) Active, not recruiting G1 Therapeutics, Inc. Phase 2 2017-02-07 This is a study to investigate the potential clinical benefit of trilaciclib (G1T28) in preserving the bone marrow and the immune system, and enhancing chemotherapy antitumor efficacy when administered prior to carboplatin and gemcitabine (GC therapy) for patients with metastatic triple negative breast cancer. The study is open-label and approximately 90 patients will be randomly assigned (1:1:1 fashion) to 1 of the 3 following treatment groups: - Group 1: GC therapy (Days 1 and 8 of 21-day cycles) only (n=30) - Group 2: GC therapy (Days 1 and 8) plus trilaciclib (G1T28) on Days 1 and 8 of 21-day cycles (n=30) - Group 3: GC therapy (Days 2 and 9) plus trilaciclib (G1T28) on Days 1, 2, 8, and 9 of 21-day cycles (n=30) The study will include 3 study phases: Screening Phase, Treatment Phase, and Survival Follow-up Phase. The Treatment Phase begins on the day of first dose with study treatment and completes at the Post-Treatment Visit.
NCT03041311 ↗ Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Extensive Stage Small Cell Lung Cancer (SCLC) Active, not recruiting G1 Therapeutics, Inc. Phase 2 2017-04-07 This is a study to investigate the potential clinical benefit of trilaciclib (G1T28) in preserving the bone marrow and the immune system, and enhancing antitumor efficacy when administered with carboplatin, etoposide, and atezolizumab (E/P/A) therapy in first line treatment for patients with newly diagnosed extensive-stage SCLC. The study is a randomized, double-blinded, placebo-controlled design. The study will include 3 study phases: Screening Phase,Treatment Phase (induction part + maintenance part), and Survival Follow-up Phase. The Treatment Phase begins on the day of first dose with study treatment and completes at the Post-Treatment Visit. Approximately, 100 patients will be enrolled in the study.
NCT04607668 ↗ Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC): Recruiting G1 Therapeutics, Inc. Phase 3 2020-10-16 This is a randomized, double-blind, placebo-controlled, global, multicenter, Phase 3 trial evaluating the impact of trilaciclib on myelopreservation and anti-tumor efficacy when administered prior to FOLFOXIRI/bevacizumab in patients with pMMR/MSS mCRC who have not received systemic therapy for metastatic disease.
NCT04799249 ↗ Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC) Recruiting G1 Therapeutics, Inc. Phase 3 2021-04-15 This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of trilaciclib versus placebo administered prior to gemcitabine and carboplatin in patients receiving first- or second-line treatment for locally advanced unresectable/metastatic TNBC.
NCT04863248 ↗ Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Docetaxel for Metastatic Non-Small Cell Lung Cancer (NSCLC) (PRESERVE 4) Recruiting G1 Therapeutics, Inc. Phase 2 2021-04-16 This is a randomized, double-blind, placebo-controlled, global, multicenter, Phase 2 trial evaluating the effect of trilaciclib on overall survival when administered prior to docetaxel in patients with mNSCLC treated in the 2nd or 3rd line setting.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for TRILACICLIB DIHYDROCHLORIDE

Condition Name

Condition Name for TRILACICLIB DIHYDROCHLORIDE
Intervention Trials
Small Cell Lung Cancer 3
Extensive-stage Small-cell Lung Cancer 3
Breast Cancer 3
Breast Neoplasm 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for TRILACICLIB DIHYDROCHLORIDE
Intervention Trials
Lung Neoplasms 9
Breast Neoplasms 7
Small Cell Lung Carcinoma 7
Triple Negative Breast Neoplasms 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for TRILACICLIB DIHYDROCHLORIDE

Trials by Country

Trials by Country for TRILACICLIB DIHYDROCHLORIDE
Location Trials
United States 123
Spain 10
China 9
Ukraine 6
Italy 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for TRILACICLIB DIHYDROCHLORIDE
Location Trials
Texas 8
California 8
Florida 7
Missouri 6
Virginia 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for TRILACICLIB DIHYDROCHLORIDE

Clinical Trial Phase

Clinical Trial Phase for TRILACICLIB DIHYDROCHLORIDE
Clinical Trial Phase Trials
Phase 4 2
Phase 3 3
Phase 2 13
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for TRILACICLIB DIHYDROCHLORIDE
Clinical Trial Phase Trials
Recruiting 9
Not yet recruiting 7
Active, not recruiting 3
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for TRILACICLIB DIHYDROCHLORIDE

Sponsor Name

Sponsor Name for TRILACICLIB DIHYDROCHLORIDE
Sponsor Trials
G1 Therapeutics, Inc. 15
Jiangsu Simcere Pharmaceutical Co., Ltd. 2
Shandong Provincial Cancer Hospital 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for TRILACICLIB DIHYDROCHLORIDE
Sponsor Trials
Industry 18
Other 16
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.